CU6 Clarity Pharmaceuticals Ltd
- 5.190
- +0.010+0.19%
Clarity Pharmaceuticals Ltd News
Clarity Pharmaceuticals Confirms Isotope Supply Continuity for Clinical Trials
Clarity Pharmaceuticals (ASX:CU6) confirmed the supply continuity of the isotope copper-67 for use in three ongoing clinical trials, according to a Friday filing with the Australian bourse. The radiop
Why Clarity Pharmaceuticals, Life360, Ramsay Health Care, and Spartan Resources Shares Are Rising Today
The S&P/ASX 200 Index (ASX: XJO) is having a subdued session on Tuesday and is trading slightly lower. In afternoon trade, the benchmark index is down 0.1% to 7,754.1 points.
Is Clarity Pharmaceuticals Ltd (ASX:CU6) Trading At A 48% Discount?
Why Catapult, Clarity, Pro Medicus, and Qantas Shares Are Rising Today
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another decline. At the time of writing, the benchmark index is down 0.5% to 7,625.1 points.
3 ASX All Ords Shares Smashing New Multi-year Highs While the Market Sinks
The All Ordinaries Index (ASX: XAO) is down 0.5% in late morning trade on Thursday, but that's not holding back these three high-flying ASX All Ords shares.
Clarity Pharmaceuticals Signs Supply Deal for Copper Isotope
Clarity Pharmaceuticals (ASX:CU6) signed a deal with supplier SpectronRx for the provision of the copper-64 isotope for upcoming clinical trials, including a pivotal phase three study, according to a
Clarity Pharmaceuticals Target Price Riased 44% to A$4.50/Share by Wilsons>CU6.AU
Clarity Pharmaceuticals Target Price Riased 44% to A$4.50/Share by Wilsons>CU6.AU
Clarity Pharmaceuticals Target Price Raised 2.6% to A$4.00/Share by Bell Potter>CU6.AU
Clarity Pharmaceuticals Target Price Raised 2.6% to A$4.00/Share by Bell Potter>CU6.AU
Clarity Pharmaceuticals Completes AU$10.8 Million Retail Entitlement Offer
Clarity Pharmaceuticals (ASX:CU6) has completed an about AU$10.8 million retail entitlement offer at AU$2.55 per new share, according to a Wednesday Australian bourse filing. The retail component now
Clarity Pharmaceuticals Price Target Raised 2% to A$3.12/Share by Wilsons
Clarity Pharmaceuticals Price Target Raised 2% to A$3.12/Share by Wilsons
Clarity Pharmaceuticals Signs Supply Agreement With NorthStar Medical Radioisotopes
Clarity Pharmaceuticals (ASX:CU6) signed a clinical supply agreement with NorthStar Medical Radioisotopes for the production of 67Cu-SAR-bisPSMA drug product for Phase I/II and Phase III trials for pr
Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip Are Sinking Today
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on track to end the shortened week on a positive note. At the time of writing, the benchmark index is up 0.9% to 7,889.3 points.
Clarity Pharmaceuticals Concludes Placement and Institutional Entitlement Offer; Shares Decline 4%
Clarity Pharmaceuticals (ASX:CU6) finalized the placement and institutional entitlement offer segment of its capital-raising initiative, accumulating a total of AU$110 million, according to a Thursday
Clarity Pharmaceuticals Price Target Cut 10% to A$3.10/Share by Jefferies
Clarity Pharmaceuticals Price Target Cut 10% to A$3.10/Share by Jefferies
Clarity Pharmaceuticals to Raise AU$121 Million via Fully Underwritten Equity Raising
Clarity Pharmaceuticals (ASX:CU6) launched a fully underwritten equity raising of AU$121 million, before costs, according to a Tuesday filing with the Australian Securities Exchange. The offer will co
Clarity Pharmaceuticals' SECuRE Trial Treats First Participant in Last Dose Escalation Cohort; Shares Down 5%
Clarity Pharmaceuticals (ASX:CU6) confirmed that the first participant in cohort four in the theranostic SECuRE trial has been treated with the 67Cu-SAR-bisPSMA product at 12 gigabecquerel, according
Why This Exciting ASX Biotech Stock Could Be a Future Star
Clarity Pharmaceuticals Ltd (ASX: CU6) shares have been on fire over the last 12 months.
Why This ASX Biotech Stock Could Rise a Massive 40%
If you're on the lookout for big returns, then you may want to check out Clarity Pharmaceuticals Ltd (ASX: CU6).
Clarity Pharmaceuticals Target Price Raised 9.7% to A$3.05/Share by Wilsons>CU6.AU
Clarity Pharmaceuticals Target Price Raised 9.7% to A$3.05/Share by Wilsons>CU6.AU
Clarity Pharmaceuticals Prostate Cancer Trial Advances
Clarity Pharmaceuticals Ltd (ASX:CU6) has completed cohort three and advanced cohort four of its multi-dose SECuRE prostate cancer trial. The SECuRE trial is to determine the safety and efficacy of Cl
Analysis
Price Target
No Data
